Omalizumab, the monoclonal antibody to IgE, was the first biologic licensed in the United Sates (US) in 2003 in adults and children (>12 years) and by 2009 it was approved in the US and Europe for all patients with asthma from the age of 6 years. The gene discussed is IGHE; the disease is asthma.